TREFOIL THERAPEUTICS
Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment o... f ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.
TREFOIL THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2014-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.trefoiltherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
858.294.0401
Email Addresses:
[email protected]
Total Funding:
85.78 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Google Tag Manager Apple Mobile Web Clips Icon Google Analytics WordPress Global Site Tag ReCAPTCHA Google Universal Analytics Facebook Sharer
Similar Organizations
Casma Therapeutics
Casma Therapeutics is a biotechnology company harnessing the natural cellular process of autophagy to design new medicines.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Forge Therapeutics
Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry.
Fractyl Health
Fractyl Health is a biotechnology company that provides curative therapies for metabolic diseases.
Lassogen
Lassogen is a biotechnology company exploring lasso peptides as a way to develop new medicines.
Q32 Bio
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Hatteras Venture Partners
Hatteras Venture Partners investment in Series A - Trefoil Therapeutics
Solasta Ventures
Solasta Ventures investment in Venture Round - Trefoil Therapeutics
Bios Partners
Bios Partners investment in Series A - Trefoil Therapeutics
Correlation Ventures
Correlation Ventures investment in Series A - Trefoil Therapeutics
Hatteras Venture Partners
Hatteras Venture Partners investment in Series A - Trefoil Therapeutics
Aju IB Investment
Aju IB Investment investment in Series A - Trefoil Therapeutics
InFocus Capital Partners
InFocus Capital Partners investment in Series A - Trefoil Therapeutics
Access Biotechnology
Access Biotechnology investment in Series A - Trefoil Therapeutics
ExSight Ventures
ExSight Ventures investment in Series A - Trefoil Therapeutics
FemHealth Ventures
FemHealth Ventures investment in Venture Round - Trefoil Therapeutics
Official Site Inspections
http://www.trefoiltherapeutics.com
- Host name: 151.101.66.159
- IP address: 151.101.66.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Trefoil Therapeutics"
About Us – Trefoil therapeutics
Trefoil’s Approach . Trefoil was founded to bring forward TTHX1114, a novel engineered FGF1 (eFGF1) compound to treat corneal diseases. Lead candidate TTHX1114 is an engineered …See details»
Trefoil Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number 858.294.0401 Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs …See details»
Trefoil Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Trefoil Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 6 news, and 9 literature, Technology Platform ...See details»
Trefoil Therapeutics - LinkedIn
Trefoil Therapeutics | 1,191 followers on LinkedIn. Developing first-in-class investigational medicines for serious corneal diseases and disorders | Trefoil Therapeutics is a clinical-stage ...See details»
Trefoil Therapeutics Inc - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Trefoil Therapeutics Inc of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
Trefoil Therapeutics - Overview, News & Similar companies
Apr 24, 2023 Who is Trefoil Therapeutics. Trefoil Therapeutics is a clinical stage biotechnology company focused on leveraging its engineered FGF-1 protein technology platform to develop fi …See details»
Trefoil Therapeutics Inc - Buzzfile
Www.trefoiltherapeutics.com: There are 6 Companies located at 6330 NANCY RIDGE DR, San Diego, CA 92121 ... Research, and Management Services sector. This organization has been …See details»
Trefoil Therapeutics - Craft
Trefoil Therapeutics has 5 employees at their 1 location and $33.2 m in total funding,. See insights on Trefoil Therapeutics including office locations, competitors, revenue, financials, …See details»
Trefoil Therapeutics Company Overview, Contact Details
Mar 22, 2022 Nov 11, 2020 | trefoiltherapeutics.com Trefoil Therapeutics Inc. receives award 'People's Choice at Eyecelerator virtual conference. San Diego, CA - November 12, 2020 - …See details»
Trefoil Therapeutics Announces the Signing of a License and …
Stewart is an ophthalmologist and founder of PRN, a leading clinical ophthalmic contract research organization, and PharmaFarm which assists startups with unique innovative technology, such …See details»
Trefoil Therapeutics Selects AGC Biologics as Lead Manufacturer of ...
Feb 4, 2020 For more information, visit www.trefoiltherapeutics.com. About AGC Biologics: AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), …See details»
Trefoil Therapeutics Announces Third Tranche of $28 Million Series …
San Diego, CA, December 1, 2021 – Trefoil Therapeutics today announced that after review of the interim clinical data from the INTREPID and STORM studies, the Series A investors have …See details»
Trefoil Therapeutics Selects AGC Biologics as Lead ... - BioSpace
SEATTLE, Feb. 4, 2020 /PRNewswire/ -- AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals and Trefoil Therapeutics …See details»
Trefoil Therapeutics Picks AGC Bio to Manufacture TTHX1114
Feb 7, 2020 For more information, visit www.trefoiltherapeutics.com. About AGC Biologics: AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), …See details»
Technology - Trefoil therapeutics
Technology Overview. The technology underlying Trefoil’s engineered FGF1, TTHX1114 builds on the well-known activities of naturally-occurring (native) FGF1 to enable its use as a …See details»
Trefoil Therapeutics Announces Third Tranche of $28 Million Series …
Dec 1, 2021 Learn more at www.trefoiltherapeutics.com. Safe Harbor Statement The research discussed in this press release is preliminary and the outcome of such studies may not be …See details»
Trefoil Advances Therapeutic for Corneal Conditions
Jun 2, 2023 Trefoil Therapeutics CEO David Eveleth, Ph.D. is excited about the results of the Phase 2 study of its lead drug candidate, an engineered form of Fibroblast Growth Factor …See details»
Clinical Trials – Trefoil therapeutics
Trefoil Therapeutics is dedicated to advancing novel engineered FGF1 (eFGF1) products to treat corneal diseases and disorders. We have ongoing laboratory research and are actively …See details»
Trefoil Therapeutics Announces First Patient Dosed in Phase 1 …
Topical formulation of TTHX1114 has potential to accelerate the healing of epithelial defects – a leading cause of blindness worldwide. SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics, …See details»